Whilst not currently employed in routine practice, consideration should be given to routine molecular testing of these tumours for the purposes of prognostication: MMR and POLE mutations are associated with favourable outcomes, whilst TP53-mutated tumours portend a worse prognosis. This evidence concerns the gene MRC1 and neoplasm.